Device-Like System Proposed For Low-Risk Human Cell Therapies, Tissue-Based Products At US FDA

 
• By Kate Rawson
  
The FDA wants to revamp its current regulatory framework for human cell and tissue-based therapies. (Shutterstock)

More from Cell & Gene Therapies

More from Pathways & Standards